was no fatality. Valve exchange surgery was needed in four patients and embolization was seen in three patients. Conclusions This report is the largest on aerococcal IE and suggests that the prognosis is relatively favourable despite the fact that the patients are old and have significant comorbidities.
Introduction
Aerococci have been regarded as rare causes of infective endocarditis (IE) in humans [1] , but due to improved diagnostic procedures they have been increasingly reported both in IE and in other types of human infections [2] . Aerococci are easily mis-identified as streptococci, enterococci, or staphylococci and correct identification can be achieved with genetic methods [3] or more conveniently through matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) [4, 5] . Aerococcus urinae is the most common aerococcal species isolated in IE [6] [7] [8] whereas Aerococcus sanguinicola is more rarely encountered [9, 10] . Aerococcus viridans was the first aerococcal species to be identified but is a rare cause of human infections [11, 12] . The most common site of isolation for both A. urinae and A. sanguinicola is human urine [3, [13] [14] [15] [16] [17] .
A large share of published cases on aerococcal invasive A. urinae infection concerns IE, and from reports on single cases it appears that the case fatality of A. urinae IE is high [2] . Patients with A. urinae IE are typically older males with underlying urinary tract diseases [2, [6] [7] [8] . Of Abstract Purpose To define the clinical presentation of aerococcal infective endocarditis (IE) and the prevalence of synergy between penicillin and gentamicin on aerococcal isolates. Methods Cases of aerococcal IE between 2002 and 2014 were identified in the Swedish Registry of Infective Endocarditis (SRIE). MALDI-TOF MS was used to confirm species determination. The medical records were analysed and compared to cases reported to the SRIE caused by other pathogens. Results Sixteen cases of aerococcal IE, fourteen with Aerococcus urinae and two with Aerococcus sanguinicola, were confirmed. Etest-based methods and time-kill experiments suggested synergy between penicillin and gentamicin towards seven of fifteen isolates. The patients with aerococcal IE were significantly older than those with streptococci or Staphylococcus aureus IE. Most of the patients had underlying urinary tract diseases or symptoms suggesting a urinary tract focus of the infection. Seven patients with aerococcal IE presented with severe sepsis but ICU treatment was needed only in one patient and there four described cases of IE with A. sanguinicola, one fatality was reported [9, 10] . Several reports of putative Aerococcus viridans IE have been published (see [18] for references). However, correct species determination was only performed in one of these studies [19] and the aetiology in the other cases is obscure. We have previously performed population-based studies which showed that only three of the sixteen patients with A. urinae bacteremia and two of the eleven patients with A. sanguinicola bacteremia had IE. All five patients with IE described in these studies survived their infection despite significant underlying diseases [7, 10] . The optimal treatment of aerococcal IE has not been determined, but two studies have suggested that penicillin and aminoglycosides have synergistic effect on aerococci in vitro [20, 21] and, therefore, combination therapy has been used in most cases.
The Swedish Registry of Infective Endocarditis (SRIE) started in 1995, organized by the Swedish Society of Infectious Diseases. All thirty departments of infectious diseases (ID) in Sweden have participated in the registry since its inception. The ID departments have regional responsibility for care of patients with severe infections, and patients requiring acute surgery for IE are in most cases treated in ID departments during the pre-and/or postoperative period. During the 20-year period, 1995-2014, 6775 adult episodes have been registered [22] . SRIE is estimated to cover approximately 75 % of all hospital-treated episodes in Sweden with a diagnosis of IE [22] . Here, we employ the SRIE to identify cases of IE with aerococci. We reanalyse the bacterial isolates and compare the cases of aerococcal IE with cases of IE caused by staphylococci, streptococci, and enterococci reported to the same registry.
Materials and methods

Collection and analysis of isolates
The SRIE was searched for cases of IE caused by aerococci reported between 2002 and 2014. Episodes had been reported on a standardized questionnaire by mail from 1995-2007 (3702 cases), and during 2008-2014 an internet-based report has been performed with a more detailed description of the episodes (2977 cases). The relevant laboratories of clinical microbiology were contacted and aerococcal isolates were collected for reanalysis in our laboratory with MALDI-TOF MS as described in [4] . Isolates of alpha-haemolytic streptococci, reported to the SRIE to have caused IE, were collected from selected laboratories, and reanalysed by MALDI-TOF MS to detect potentially mis-identified aerococci. Bacteria were cultivated on blood agar plates in 5 % CO 2 at 37 °C . Minimal inhibitory concentration (MIC) was determined using Etests (Biomerieux, Solna, Sweden) on Müller-Hinton agar (MHA) with defibrinated horse blood and β-NAD [23] or blood agar for three isolates not growing on the MHA. For synergy testing based on Etest methodology, the method MIC:MIC was used [24] . Fractional inhibitory concentration (FIC) was defined as (MIC for benzyl penicillin in combination)/(MIC for benzyl penicillin alone) + (MIC for gentamicin in combination)/(MIC for gentamicin alone). For bactericidal synergy testing, the method described by Weinstein and Moellering [25] was used, with modification as described [26] . For the combination of benzyl penicillin and gentamicin to be considered synergistic against a given isolate, synergy, defined as a two-log difference between the combination and most effective of the individual antibiotics, had to be present at two of the three samples at a given time point and antibiotic concentration.
Data collection and statistical analysis
Clinical information on patients was collected from the SRIE and from the medical records of the respective patient. Severe sepsis was defined as described in [7] . Data from the SRIE on IE caused by enterococci, alphahaemolytic streptococci, and Staphylococcus aureus were extracted from the internet-based part of the Registry and compared to the corresponding data on aerococci. Differences were tested for statistical significance with Fischers exact test or the Wilcoxon rank number test using GraphPad Prism version 6.
The local research ethical committee approved this study (reference number 2013/182). The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Results
Aerococcal isolates
Twenty-nine cases of reported aerococcal IE were identified and the aetiology was reported as A. urinae in fifteen cases, as A. viridans in eight cases, as A. sanguinicola in one case, and as Aerococcus sp. in five cases. Twenty of these isolates were available for species determination with MALDI-TOF MS and only one of the nine isolates not available for reanalysis had been speciated with a reliable method (MALDI-TOF MS). Fourteen isolates (one of which was the MADLI-TOF-identified isolate not available for reanalysis) were found to be A. urinae, two isolates were identified as A. sanguinicola, whereas five isolates were identified as α-haemolytic streptococci. All scores were above 2.0. Due to the high frequency of mis-identification (5/20), we chose to exclude the eight cases where isolates were not available for MALDI-TOF MS analysis. We also analysed 110 isolates of α-haemolytic streptococci, reported to the SRIE to have caused IE, and no additional aerococci were identified among these isolates. Thus, for further analyses, we used the sixteen isolates securely identified as aerococci.
Aerococcal antimicrobial susceptibility
The pattern of susceptibility to relevant antimicrobials of the fifteen available isolates is given in Table 1 . As expected, all isolates had low MIC for penicillin and cefotaxime. Using for viridans streptococci, all isolates were sensitive to penicillin (S ≤ 0.25), cefotaxime (S ≤ 0.5), and vancomycin (S ≤ 2). One isolate was resistant to clindamycin (EUCAST breakpoint R > 0.5) and MIC for gentamicin was in the 1-32 mg/L range. MIC to ciprofloxacin was variable and two isolates showed values above 32 mg/L. The possible synergy between penicillin and gentamicin was tested through the MIC:MIC method and calculated fractional inhibitory concentrations (FIC) were between 0.42 and 1.75. A FIC ≤0.5 is considered as synergy and using this definition, three isolates displayed synergy. There was no correlation between the FIC value and the synergistic bactericidal effect of benzyl penicillin and gentamicin. Bactericidal synergy was noted against seven of the fifteen isolates (47 %). Synergy noted at 6 h for one isolate only and for the other six at 24 h. For some isolates, synergy was not detected but could not be ruled out either (Table 1) .
Clinical presentation of aerococcal IE
The features of patients with aerococcal IE are given in Table 2 . The patients were predominantly male (12/16) and the median age was 79 years. Two patients have been previously reported [7, 10] . Fourteen patients fulfilled the revised Dukes criteria for definite IE [27] whereas two patients had possible IE. All patients had at least two sets of blood cultures positive for aerococci and in eleven cases aerococci were the only bacteria isolated from blood. In four patients, a coagulase negative Staphylococcus was isolated from a single bottle and in one patient a single bottle grew Proteus mirabilis. None of the patients had aerococci in urinary cultures upon admission. Eleven patients had either underlying urological conditions such as prostate cancer or urinary tract catheter. Several patients had other comorbidities, such as neurological conditions (n = 7), diabetes mellitus (n = 4), non-urological malignancies (n = 2), or conditions requiring immunosuppression (n = 2). Fever was a presenting symptom in all patients and four patients had urological symptoms at presentation. At the time of admission, six patients were on treatment, or had recently finished a course, with a fluoroquinolone for suspected urinary tract infection. Three patients had been treated for aerococcal bacteremia with a short course of beta-lactam antibiotics (3-7 days i.v.) followed by peroral beta-lactams or ciprofloxacin for 5-7 days within the previous 4 weeks. Seven patients had severe sepsis upon admission and one patient required intensive care. All patients were subjected to trans-oesophageal echocardiography (TEE) and eight were shown to have mitral valve affection whereas five had aortic valve affection. Two patients without evidence of IE at TEE had new murmurs. All patients received treatment with a beta-lactam antibiotic in combination with an aminoglycoside. Median time of treatment was 28 days (range 13-44) for the beta-lactam and 10 days (range 1-40) for the aminoglycoside. Three patients had embolic events, one had an embolus to the kidney, one had cervical spondylodiscitis (also described in [7] ) and one had an occlusion of the medial cerebral artery. Surgery was needed in four patients due to progressive cardiac failure. All patients survived the hospital stay.
Comparison of IE caused by aerococci and IE caused by other bacteria
Information from the SRIE on the cases of IE caused by aerococci was compared to the information on IE caused by S. aureus (n = 1013), alpha-haemolytic streptococci (n = 722), and enterococci (n = 296) ( Table 3 ). For differences reaching significance, the p value is given. Notably, the age of the patient with aerococcal IE was significantly higher than that of patients with IE cased by streptococci or S. aureus. There was a higher prevalence of cancer among patients with aerococcal IE as compared to those with S. aureus IE. None of the cases with aerococcal IE was rightsided or occurred in patients with intravenous drug use (IVDU) and this was significantly different from the situation in S. aureus IE. There were no statistically significant differences between patients with aerococcal IE and those infected with the other organisms in the proportion of patients with predisposing heart conditions or in the proportion of cases affecting the mitral and aortic valve, respectively. There was a longer time from the onset of symptoms to initiation of appropriate treatment (onset of treatment in Table 3 ) for patients with aerococcal IE compared to patients with S. aureus IE though the difference was not significant. Length of treatment did not vary significantly between the groups but patients with S. aureus IE received aminoglycosides for a significantly shorter period of time. There were no statistically significant differences in outcome measures between patients with aerococcal IE and IE with other bacteria though mortality and proportion of patients with embolization were higher among patients with S. aureus IE. Table 2 a Indicates the isolates described previously [7, 10] Italics values indicate the two isolates of A. sanguinicola 
Discussion
From published cases on IE caused by aerococci, it appears that the condition is rare and that the prognosis is unfavourable, especially for A. urinae. This study demonstrates that the prognosis of aerococcal IE is relatively favourable in the setting of the Swedish health care system despite the patients being very old and having significant comorbidities. Though seven of the patients presented with signs of severe sepsis, a condition generally considered to have a relatively poor prognosis, all patients survived. Despite being the largest study on aerococcal IE, the study is underpowered to detect differences in prognosis between aerococcal IE and IE with other organisms. We believe, however, that the prognosis of aerococcal IE is better than that of IE with S. aureus both in terms of mortality and the frequency of embolization. The unfavourable prognosis indicated by previous case reports is most likely the results of a bias to publish more dramatic presentations of disease.
Patients with aerococcal IE were, as in previous reports, old, male, and with underlying urological diseases. The higher proportion of patients with cancer in the aerococcal group is largely explained by the three cases with prostate cancer among those patients. A large proportion of the patients reported here presented with signs and symptoms which were interpreted as urinary tract infections and many had received treatment with fluoroquinolones, which have a questionable effect against aerococci. Despite this, aerococci were not identified in urinary cultures which confirm the findings in our previous studies [7, 10] . We still believe that the urinary tract is the focus of the initial bacteremia in most cases of aerococcal IE and that more sensitive methods for detection of aerococci in urine are needed.
The combination of benzyl penicillin and gentamicin has been widely used for the treatment of aerococcal IE, including all cases described herein. The findings of this study raise the question of whether adding gentamicin is beneficial for the patient as synergy could only be shown for a minority of the isolates. Notably, synergy was not detected for the A. sanguinicola isolates and synergy for this species has this far not been documented. As we did not find any correlation between FIC and bactericidal synergy, there is no method that could be used in the routine clinical laboratory setting to identify which patients should receive combination treatment. Three patients had a preceding episode of A. urinae bacteremia which was treated with intravenous antibiotics beta-lactam antibiotics without the addition of aminoglycosides for a shorter period of time (3-7 days) which evidently was insufficient since they had a recurrence. However, it is not clear if these patients had IE already at the first presentation. There were no recurrences after IE-treatment among our patients. A limitation of the study design is its retrospective nature. This limited patient information to that which had already been entered into the medical records or the SRIE. The retrospective nature also limited the number of isolates that we could re-speciate (20/29) and analyse for antibiotic susceptibility. Despite these drawbacks, this study is by far the largest reporting IE with aerococci. We excluded thirteen patients reported to the SRIE, since the species determination was incorrect (n = 5) or unreliable (n = 8).
Of the twenty-one isolates tested with MALDI-TOF MS, sixteen were aerococci but five isolates were streptococci.
The lack of additional aerococci among alpha-haemolytic streptococci reported to the SRIE indicates that aerococci are not very often mis-identified in Swedish laboratories, at least not in blood cultures. Eight isolates had been reported to the SRIE as A. viridans and this species has been implicated in many IE cases but species determination has on most occasions been inadequate [12, 28] . This study suggests that A. urinae is the most common cause of aerococcal IE and that A. viridans is a rare cause of IE. With the introduction of MALDI-TOF MS, which correctly differentiates between A. viridans and A. sanguinicola, more isolates of A. sanguinicola will likely be identified. The use of MALDI-TOF MS in species determination of bacteria will likely also reveal that aerococcal IE is not so uncommon as previously thought.
We suggest that IE should be considered in all patients with aerococcal bacteremia and that the urinary tract should be considered as the point of entry of the bacteria. Before combination therapy using penicillin and an aminoglycoside is instituted, the potential risk for aminoglycoside side-effects must be carefully weighed against the potential benefit of a potential antibacterial synergy.
